{'52WeekChange': -0.08204627,
 'SandP52WeekChange': 0.0644362,
 'address1': '100 Summer Street',
 'address2': 'Suite 2300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.51,
 'askSize': 1200,
 'averageDailyVolume10Day': 2055475,
 'averageVolume': 2144049,
 'averageVolume10days': 2055475,
 'beta': 1.373669,
 'beta3Year': None,
 'bid': 9.5,
 'bidSize': 4000,
 'bookValue': -0.449,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.815,
 'dayLow': 9.36,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 11.079,
 'enterpriseToRevenue': 3.916,
 'enterpriseValue': 1721478784,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 9.984,
 'fiftyTwoWeekHigh': 14.1,
 'fiftyTwoWeekLow': 7.91,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 141142533,
 'forwardEps': 0.54,
 'forwardPE': 17.61111,
 'fromCurrency': None,
 'fullTimeEmployees': 317,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.03205,
 'heldPercentInstitutions': 1.1471801,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1554163200,
 'lastSplitFactor': '1194:1000',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ironwoodpharma.com',
 'longBusinessSummary': 'Ironwood Pharmaceuticals, Inc., a healthcare company, '
                        'focuses on the development and commercialization of '
                        'gastrointestinal (GI) products. The company markets '
                        'linaclotide, a guanylate cyclase type-C agonist for '
                        'the treatment of adults suffering from irritable '
                        'bowel syndrome with constipation (IBS-C) or chronic '
                        'idiopathic constipation (CIC) under the LINZESS name '
                        'in the United States and CONSTELLA name in the Canada '
                        'and European Union; MD-7246, an oral, intestinal, '
                        'non-opioid, pain-relieving agent for patients '
                        'suffering from abdominal pain associated with GI '
                        'diseases; and IW 3718, a gastric retentive '
                        'formulation of a bile acid sequestrant, which is in '
                        'Phase III clinical trials for the treatment of GERD. '
                        'Ironwood Pharmaceuticals, Inc. has collaboration '
                        'agreements with Allergan plc and AstraZeneca AB to '
                        'develop and commercialize linaclotide for the '
                        'treatment of IBS-C, CIC, and other gastrointestinal '
                        '(GI) conditions in North America, China, Hong Kong, '
                        'Macau, and Japan, as well as a license agreement with '
                        'Astellas Pharma Inc. to develop and commercialize '
                        'linaclotide for the treatment of IBS-C, CIC, and '
                        'other GI conditions in Japan. The company was '
                        'formerly known as Microbia, Inc. and changed its name '
                        'to Ironwood Pharmaceuticals, Inc. in April 2008. '
                        'Ironwood Pharmaceuticals, Inc. was founded in 1998 '
                        'and is headquartered in Boston, Massachusetts.',
 'longName': 'Ironwood Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1515694464,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_31498',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 84134000,
 'nextFiscalYearEnd': 1640908800,
 'open': 9.72,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.31,
 'phone': '617 621 7722',
 'previousClose': 9.8,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 3.4476907,
 'profitMargins': 0.19138001,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.815,
 'regularMarketDayLow': 9.36,
 'regularMarketOpen': 9.72,
 'regularMarketPreviousClose': 9.8,
 'regularMarketPrice': 9.72,
 'regularMarketVolume': 3896739,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 159379008,
 'sharesPercentSharesOut': 0.1666,
 'sharesShort': 26556263,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 24247334,
 'shortName': 'Ironwood Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.261,
 'shortRatio': 10.35,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'IRWD',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.535,
 'trailingPE': 17.7757,
 'twoHundredDayAverage': 10.823166,
 'volume': 3896739,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ironwoodpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02110'}